AXIM Biotechnologies, Inc. announced the receipt of notification by the United States Patent & Trademark Office of several patent allowances. AXIM has been developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including, for example, SARS-Cov-2, Lactoferrin, IgE, Lacritin, MMP-9. This innovative platform allows clinicians to detect with greater speed and accuracy different conditions that, e.g., allow for point of care testing of viruses, diseases, and conditions such as Dry Eye Disease. Lower concentrations of Lacritin may diagnose several eye diseases, including Blepharitis, Sjogren's syndrome, Dry Eye Disease and other inflammatory conditions.

Tear Sample Collectors Systems and Methods. 1 Utility Patent Application: Tear fluid analysis contributes to the greater understanding of various ocular and systemic diseases and obtaining adequate samples for tear analysis requires effective collection methods. Most tear sample collectors on the market use capillary designs that are intimidating to the patient.

The invention relates to a laminated and looped tear sample collector that is cost-effective, easy to use and soft and non-intimidating to the user and patient. Use of Micromesh Materials in Diagnostic Devices. 1 Provisional Patent Application: When small sample sizes (0.1-2 microliters) are used, such as tears, there is a need for the sample to be spread out over application area for a proper flow.

The invention allows dispersion of a small sample volume into mesh cells over a wide area controllable by the mesh size. This enables homogeneous sample dispersion over the entire sample application area. CANCER DIAGNOSTICS Systems and Methods for Rapid Diagnostic for Various Cancers.

1 Allowed Patent Application: QSOX1-L, a splice variant of QSOX1, has been identified as a novel biomarker of bladder cancer and possibly other cancers in serum. Such test kit and method can advantageously improve the diagnosis and therapy of various diseases. New DIAGNOSTIC test: Fentanyl Diagnostic Test.1 Provisional Patent Application: Researches have reported that broadly neutralizing antibodies may prevent lethality from the fentanyl class of synthetic opioids.

The test can be used to monitor the vaccine's response and help decide when a booster is needed. New TECHNOLOGY Point of Care Apparatus and Methods for Detecting Cancer Using Electrochemical Impedance or Capacitance Spectroscopy 1 allowed patent. 1 Allowed Patent, 1 Utility Patent Application The presence of cancer biomarkers or other analytes can be detected in the bodily fluid using EIS or ECS in devices, such as handheld point-of-care devices.

The devices, as well as systems and methods, utilize using EIS or ECS in combination with an antibody or other target-capturing molecule on a working electrode. Imaginary impedance or phase shift, as well as background subtraction, also may be utilized.